Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Guangdong Association of Clinical Trials
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Signed an informed consent form
2. Patients aged ≥18
3. Histologically or cytologically confirmed stage III or IV non-squamous non-small cell lung cancer (NSCLC) per the American Joint Committee on Cancer (AJCC) 8th Edition staging system
4. at least one measurable lesion according to RECIST 1.1 criteria
5. ECOG PS 0-1.
6. Subjects must have adequately documented disease progression following prior treatment with PD-1/PD-L1 inhibitors (administered as monotherapy or in combination with chemotherapy)
8\. The most recent tumor tissue sample prior to the first dose of the study drug demonstrated PD-L1 TPS \<1% 9. appropriate organ function
You may not be if
1. Known presence of sensitizing mutations in EGFR, EGFR exon 20 insertions, ALK fusions, ROS1 fusions, RET fusions, NTRK fusions, BRAF V600E mutations, MET exon 14 skipping mutations, or HER2 sensitizing mutations (for other genetic alterations, eligibility will be determined by the Biomarker Committee on a case-by-case basis).
2. Patients with symptomatic, neurologically unstable central nervous system (CNS) metastases, or CNS diseases that require increased steroid doses to control
3. Prior lines of systemic anti-tumor therapy ≥ 2.
Clareo Health | QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
